September 2022 Content Release Copied

Clinical Profile Documentation

AJCC 8^th Edition Staging

This release contains updated TNM values, Stage Groupings, and Template functionality to align with AJCC Version 9 conditions for:

• Cervical Cancer

Users will see updated values and descriptions for the Primary Tumor Type (T), Regional Lymph Nodes (N), and Distant Metastasis (M), documentation points for Cervical Cancer.

• T1, T1a, T2, T2a, and T3 are now available
• N1 and N2 are now available
• cM0 is no longer available and M0 is now available

The staging calculator will display updated Stage values based on the changes to the staging groups. The new content does not affect previous charting documented on existing patients. A summary table is provided below.

All previous charting is brought forward during a subsequent visit, just as it did prior to this release.

Tumor Type	Node	Metastasis	Stage
T1	N0	M0	I
T1a	N0	M0	IA
T1b	N0	M0	IB
T2	N0	M0	II
T2a	N0	M0	IIA
T3	N0	M0	III
TX, T0, T1-3	N1	M0	IIIC1
TX, T0, T1-3	N2	M0	IIIC2

Biomarker Guidance

A new informational row called BIOMARKER TESTING will display NCCN biomarker testing guidelines for Colon and Rectal cancers in the Details section, when adding a new Problem in a patient’s Clinical Profile. This information can be used to place biomarker testing in the Orders tab.

This feature is part of an effort to support biomarker testing and optimize your patients’ treatment plans in iKnowMed.

Problems

Additions

The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.

ERBB2 (HER2) mutation testing result is now available for Lung Cancer, Non-small Cell (NSCLC) with the following documentation points:

• ERBB2 (HER2) Mutation Positive
• ERBB2 (HER2) Mutation Negative
• Unknown

The following items are available for documentation in Problems and appear in the Charge Capture Report (CCR). Additional ICD-10 codes* may be displayed to present the surrounding nodes.

The Vasculitis problem group now contains the following problems:

• Wegener’s granulomatosis with renal involvement (disorder)
• Wegener’s granulomatosis without renal involvement (disorder)

Please see APPENDIX A for a complete summary of changes.

Order Sets

Additions

• RTC APP injection
• RTC MD extended office visit
• RTC MD injection
• RTC MD scan review
• RTC nurse for new treatment
• RTC pain pump refill

Updates

The Pembrolizumab Lab Order Bundle Q28D has been updated to Immunotherapy lab order bundle. Only the name has been updated, all contents of the Order Set to remain the same.

Lab Analytes & Panels

Additions

• ABL1 kinase mutation analysis panel
• ABL1 kinase mutation analysis result
• Acute 10 color flow cytometry leukemia/lymphoma panel (Global)
• Acute 10 color flow panel result
• Adaptive bio clonoSEQ panel
• Adaptive bio clonoSEQ result
• Alpha thalassemia reflex
• Alpha-galactosidase, % mean normal activity
• Anti-MPO Ab, units
• Anti-myeloperoxidase (MPO) Ab panel
• BCR-ABL qRT-PCR panel
• BCR-ABL qRT-PCR result
• Biotheranostics BCI panel
• Biotheranostics BCI result
• CD8 suppressor, absolute, /uL
• Chlamydia culture source
• Endeavor comprehensive solid tumor profile
• Endeavor comprehensive solid tumor profile result
• Epstein-Barr DNA quant, PCR, IU/mL
• Er/Pr/Her2 IHC/FISH panel
• Er/Pr/Her2 IHC/FISH result
• FGF 23 (Fibroblast growth factor 23) panel
• FGF 23 (Fibroblast growth factor 23) result
• FGF 23 panel
• FoundationOne Liquid CDX panel
• FoundationOne Liquid CDX result
• G6PD, RBC count
• Gliadin(DP) ab, IgA, ELiAU/mL
• Gliadin(DP) ab, IgG, ELiAU/mL
• GM1 IgM Autoantibodies interpretation
• GM1 IgM Autoantibodies interpretation pane
• GM1 IgM Autoantibodies panel
• GM1 IgM Autoantibodies, %
• GP2
• Gyn pap IG panel chlamydia, NAA
• Gyn pap IG panel diagnosis
• Gyn pap IG panel gonococcus, NAA
• Gyn pap IG panel HSV 1, NAA
• Gyn pap IG panel HSV 2, NAA
• Gyn pap IG panel note
• Gyn pap IG panel performed by
• Gyn pap IG panel specimen adequacy
• Gyn pap IG panel test methodology
• Gyn pap IG panel trich vag, NAA
• Gyn pap IG w/CT, NG, TV, HSV 1/2 NAA panel
• Hemoglobinopathy+ferritin w/alpha thalassemia
• Rfx panel
• Hereditary Breast cancer panel
• Hereditary Colorectal cancer panel
• Hereditary Germline genetic panel
• Hereditary Ovarian cancer panel
• Hereditary Pancreatic cancer panel
• Hereditary Prostate cancer panel
• IgHV mutation analysis panel
• IgHV mutation analysis result
• Inivata InVisionFirst Lung panel
• Inivata InVisionFirst Lung result
• Invitae hereditary hemochromatosis panel
• Invitae hereditary hemochromatosis result
• Invitae Hyperparathyroidism panel
• Invitae Hyperparathyroidism result
• Invitae primary immunodeficiency panel
• Invitae primary immunodeficiency result
• IPATH bone marrow panel
• IPATH bone marrow result
• IPATH peripheral blood panel
• IPATH peripheral blood result
• Lymphoma T-Cell, TCR gamma by PCR panel
• MammaPrint panel
• MedFusion CLL panel (NGS)
• MedFusion CLL panel (NGS) results
• MedFusion LungSeq Concurrent panel
• MedFusion LungSeq Concurrent result
• MedFusion MPN Mini panel (NGS)
• MedFusion MPN Mini panel (NGS) result
• MedFusion MPN profile (NGS)
• MedFusion MPN profile (NGS) result
• MedFusion Myeloid profile (NGS)
• MedFusion Myeloid profile (NGS) result
• NeoGenomics CLL profile (NGS + FISH)
• NeoGenomics CLL profile (NGS + FISH) result
• Neogenomics Colorectal tumor profile
• NeoGenomics Flow MRD panel
• NeoGenomics Flow MRD result
• NeoGenomics MPN Reflex (NGS) panel
• NeoGenomics MPN Reflex (NGS) result
• NeoGenomics Myeloid profile (NGS)
• NeoGenomics Myeloid profile (NGS) result
• Oncomap panel
• Oncomap result
• OncotypeDX panel
• OnkoSight Advanced NGS JAK2, MPL and CALR reflex to
• OnkoSight Advanced NGS JAK2, MPL and CALR reflex to
• OnkoSight advanced NGS MDS clinical trials 1
• OnkoSight advanced NGS MDS detailed genetic interpretation 1
• OnkoSight advanced NGS MDS interpretation summary
• OnkoSight advanced NGS MDS methods
• OnkoSight advanced NGS MDS panel
• OnkoSight advanced NGS MDS panel result
• OnkoSight advanced NGS MDS references 1
• OnkoSight advanced NGS MDS report footer
• OnkoSight advanced NGS MDS technical summary
• OnkoSight advanced NGS myeloid panel
• OnkoSight advanced NGS myeloid panel result
• OnkoSight NGS JAK2, MPL and CALR reflex to MPN panel clinical trials 1
• OnkoSight NGS JAK2, MPL and CALR reflex to MPN panel detailed genetic interpretation 1
• OnkoSight NGS JAK2, MPL and CALR reflex to MPN panel interpretation summary
• OnkoSight NGS JAK2, MPL and CALR reflex to MPN panel methods
• OnkoSight NGS JAK2, MPL and CALR reflex to MPN panel references 1
• OnkoSight NGS JAK2, MPL and CALR reflex to MPN panel report
• OnkoSight NGS JAK2, MPL and CALR reflex to MPN panel report footer
• OnkoSight NGS JAK2, MPL and CALR reflex to MPN panel technical summary
• Postmenopausal interp: HIGH
• Postmenopausal interp: LOW
• Premenopausal interp: HIGH
• Premenopausal interp: LOW
• Rfx to HBc IgM
• Rh(D) Blood type
• Rh(D) genotype
• Rh(D) genotype panel
• SmartGenomics NGS expanded heme panel
• SmartGenomics NGS expanded heme result
• SureSwab advanced bacterial vaginosis panel
• SureSwab advanced bacterial vaginosis,TMA
• TCR gamma, PCR
• TP53 mutation analysis panel
• TP53 mutation analysis result

Medications

Additions

• AZD8853 invest IV
• Cool Magic Transdermal Gel Sheet
• Domvanalimab invest IV
• Epcoritamab invest Subcutaneous
• GRN-300 invest Oral
• Imlunestrant invest (LY3484356 invest Oral)
• INCB123667 invest Oral
• Ketamine Compounded Sublingual
• MORAb-202 invest IV
• MTL-CEBPA invest IV
• NC410 invest IV
• PF-07104091 invest Oral
• PF-07220060 invest Oral
• PRO1184 invest IV

Updates

Medication	Update
Arsenic Trioxide IV	New Max Single Dose available: 45 mg
Axicabtagene Ciloleucel IV	New Sig available: 2 x 10e8 CARpos viable T cells intravenously Piggyback once
AZD9833 invest Oral	New Dose Units available: Mg/kg Mg/m2 New Default Sig: 75 mg orally daily
Burosumab-twza Subcutaneous	New Dose Units available: Mg/kg Mg/m2
Deferasirox Oral (Exjade)	New Dose Units available: Mg/kg Mg/m2
DS-8201a invest IV	New Dose Units available: Mg Mg/m2
Ibrutinib Oral Suspension	New Default Sig available: 216 mL orally daily
NT-I7 invest Intramuscular	New Dose Units available: Mcg Mcg/m2 New Default Sig: 1,200 mcg/kg intramuscularly As Directed
NUV-868 invest Oral	New Form available: 20 mg capsule
RGX-104 invest Oral	New Forms available: 40 mg softgel 60 mg softgel 80 mg capsule
Tizanidine Oral	New Default Form available: 4 mg tablet

Regimen Library

Additions

Regimen Name	Diagnosis
Brentuximab vedotin D1,8 + Ifosfamide CIV D2 + Carboplatin D2 + Etoposide D1-3 (ICE) Q21D	Lymphoma, Hodgkin (HL)
Capecitabine D1-14 + Cisplatin + Nivolumab Q21D	Esophageal Cancer (Parent)
Danazol Q30D	Myelofibrosis
Daratumumab IV Q28D (Post-Transplant Maintenance)	Multiple Myeloma (MM)
Daratumumab SQ Q28D (Post-Transplant Maintenance)	Multiple Myeloma (MM)
Deferasirox (Exjade) Q30D (Transfusional Iron Overload)	All Problems
Pemigatinib Q28D (Myeloid/Lymphoid Neoplasms)	Myeloproliferative Disorder; Leukemia, Acute Myeloid (AML); Lymphoma, Non-Hodgkin (NHL) (Parent); Leukemia, Acute Lymphocytic (ALL); Myelodysplastic Syndrome (MDS)
Risankizumab-rzaa SQ Q56D (Crohn’s Maintenance)	Crohn’s Disease
Rituximab IV Q7D	Immune thrombocytopenia (disorder)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

• All Problems
• Breast Cancer
• Colon Cancer
• Leukemia, Chronic Lymphocytic (CLL)
• Lymphoma, Non-Hodgkin (NHL) (Parent)
• Prostate Cancer
• Waldenstrom’s Macroglobulinemia

Renames

<thead

Previous Name	New Name
Darbepoetin alfa Q7D	Darbepoetin alfa D1,15 + Lenalidomide D1-21 Q28D (MDS)
Darbepoetin alfa D1,15 + Lenalidomide D1-21 Q28D	Darbepoetin alfa Q7D (CKD on Dialysis, Chemotherapy- Induced Anemia)
Epoetin alfa D1,8,15,22 + Lenalidomide D1-21 Q28D	Epoetin alfa D1,8,15,22 + Lenalidomide D1-21 Q28D (MDS)
Fam-Trastuzumab Deruxtecan-nxki Q21D (Breast)	Fam-Trastuzumab Deruxtecan-nxki (5.4 mg/kg) Q21D
Fam-Trastuzumab Deruxtecan-nxki Q21D	Fam-Trastuzumab Deruxtecan-nxki (6.4 mg/kg) Q21D
Lutetium Lu 177 dotatate Q56D	Lutetium Lu 177 dotatate (Lutathera) Q56D

Research Regimens

Updates

The USOR Clinical Trials listed in the table below are updated:

	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
USOR 18020		X
USOR 18194	X
USOR 18261	X	X	X
USOR 18283	X		X	Now available: USOR 18283 Avelumab Q14D USOR 18283 Avelumab Q14D (Maintenance Therapy) USOR 18283 Gemcitabine D1,8 + Carboplatin Q21D USOR 18283 Sacituzumab govitecan D1,8 + Zimberelimab D1 + Domvanalimab Q21D USOR 18283 Sacituzumab govitecan D1,8 + Zimberelimab Q21D USOR 18283 Sacituzumab govitecan D1,8 + Zimberelimab Q21D (Maintenance Therapy) USOR 18283 Sacituzumab govitecan D1,8 Q21D USOR 18283 Zimberelimab Q21D No longer available: USOR 18283 Cisplatin (split dose) D1,8 + Sacituzumab govitecan D1,8 Q21D + Avelumab Q14D USOR 18283 Cisplatin D1 + Sacituzumab govitecan D1,8 Q21D + Avelumab Q14D
USOR 20133				Now available: USOR 20133 Tafasitamab or Placebo D1,8,15 + Lenalidomide or Placebo D1- 10 + Rituximab IV + CHOP Q21D No longer available: USOR 20133 Tafasitamab or Placebo D1,8,15 + Lenalidomide or Placebo D1- 10 + Rituximab IV + CHOP Q21D Reference USOR 20133 Tafasitamab or Placebo D1,8,15 + Lenalidomide or Placebo D1- 10 + Rituximab IV BIOSIMILAR + CHOP Q21D
USOR 20229	X
USOR 20245	X
USOR 20318	X	X	X
USOR 20396	X	X	X
USOR 20398	X	X
USOR 20408		X	X
USOR 21239	X		X
USOR 21346		X
USOR 21462	X	X	X	Now available: USOR 21462 Booster Series GLSI-100 or Placebo (Dose 7-11) + DTH Skin Test or Placebo USOR 21462 DTH Skin Test or Placebo (Month 37+) USOR 21462 Primary Immunization Series GLSI-100 or Placebo (Dose 1-6) + DTH Skin Test or Placebo No longer available: USOR 21462 Primary Immunization Series GLSI-100 or Placebo (Dose 1-6) + DTH Skin Test USOR 21462 Booster Series GLSI-100 or Placebo (Dose 7-11) + DTH Skin Test
USOR 21469				Now available: USOR 21469 Loncastuximab Tesirine + Rituximab IV fb SQ Q21D USOR 21469 Loncastuximab Tesirine + Rituximab IV Q21D No longer available: USOR 21469 Loncastuximab Tesirine + Rituximab IV BIOSIMILAR fb SQ Q21D USOR 21469 Loncastuximab Tesirine + Rituximab IV BIOSIMILAR Q21D USOR 21469 Loncastuximab Tesirine + Rituximab IV fb SQ Q21D Reference USOR 21469 Loncastuximab Tesirine + Rituximab IV Q21D Reference
USOR 21501	X
USOR 21536	X	X

Billing & HCPCS Codes

At the time of the SEPT_22 release note publication, CMS has not released the October 2022 HCPCS updates.

HCPCS updates effective on October 1, 2022 have been completed based on the CMS HCPCS Application Summaries and Coding Recommendations.

Updates

Medication	HCPCS
Betibeglogene Autotemcel (Zynteglo)	J3590 per 5x 10e6 CD34+ cells
Ciltacabtagene autoleuce (Carvykti)	Q2056 per 0.5 x10e6 CARpos vbl T cells 1 x10e6 CARpos vbl T cells 1 x10e8 CARpos vbl T cells
COVID-19 Vac, BV (Ori,BA4/5) (Pfizer) (PF) IM (5 thru 11 yr) (Unapproved)	91315 per 0.2 mL 10 mcg
COVID-19 Vac, BV (Ori,BA4/5) (Pfizer) (PF) IM (12 yrs & older) (EUA)	91312 per 0.3 mL 30 mcg
COVID-19 Vac, BV (Orig,BA4/5) (Moderna) (PF) IM (18 yrs & older) (EUA)	91313 per 0.5 mL 50 mcg
COVID-19 Vaccine, mRNA, Pediatric (Moderna) (PF) IM (6 yrs thru 11 yrs) (Unapproved)	91309 per 0.5 mL 50 mcg
Faricimab-svoa intravitreal (Vabysmo)	J2777 per 0.1 mg
Filgrastim-ayow (Releuko)	Q5125 per 1 mcg
Fluorodopa F-18 IV 0.42 mCi/mL to 8.33 mCi/mL	A9602 per 1 mCi 37 MBq
Kit for Prep of Ga 68-Gozetotide IV (Locametz)	A9800 per 1 mCi 37 MBq
Lutetium lu 177 Vipivotide Tetraxetan IV 27 mCi/mL (1,000 MBq/mL)	A9607 per 1 mCi 37 MBq
Nivolumab-Relatlimab-rmbw (Opdualag)	J9298 per 4 mg 0.25 mL
Olipudase alfa-rpcp IV (Xenpozyme)	J3490 per 20 mg
Ranibizumab-nuna Intravitreal (Byooviz)	Q5124 per 0.1 mg
Risankizumab-rzaa IV (Skyrizi)	J3590 per 600 mg
Spesolimab-sbzo IV (Spevigo)	J3590 per 450 mg
Sutimlimab-jome IV (Enjaymo)	J1302 per 10 mg
Tebentafusp-tebn (Kimmtrak)	J9274 per 1 mcg
Vaccinia Immune Globulin Human IV	90393 per 6000 unit

Charge Capture

Additions

The following items are available for documentation in Problems and appear on the Charge Capture Report (CCR). Additional ICD-10 codes may display to present the surrounding nodes.

2023 ICD-10-CM

• For a complete list of October 1st ICD-10-CM updates, please visit 2023 ICD-10-CM downloads.
• For the ICD-10-CM crosswalk see 2023 Conversion Table (ZIP).

Appendix A

Problem & Codes Summary

Problem	ICD-10 Codes
Abnormal product of conception	O02.9 Abnormal product of conception, unspecified
Abnormal uterine bleeding (disorder)	N93.3 Abnormal uterine and vaginal bleeding, unspecified
Abnormal vaginal bleeding (finding)	N93.9 Abnormal uterine and vaginal bleeding, unspecified
Abscess of buttock (disorder)	L02.31 Cutaneous abscess of buttock
Abscess of lung with pneumonia	J85.1 Abscess of lung with pneumonia
Abscess of lung without pneumonia	J85.2 Abscess of lung without pneumonia
Abscess of mediastinum	J85.3 Abscess of medastinum
Actinic keratosis (disorder)	L57.0 Actinic keratosis
Acute cholecystitis (disorder)	K81.0 Acute cholecystitis
Acute gangrenous appendicitis with localized peritonitis without perforation	K35.31 Acute appendicitis with localized peritonitis and gangrene, without perforation
Acute thyroiditis (disorder)	E06.0 Acute thyroiditis
Anal abscess (disorder)	K61.0 Anal abscess
Anemia, unspecified	D64.9 Anemia, unspecified
Atrophy of cystic duct (disorder)	K82.8 Other specified diseases of gallbladder
Atrophy of gallbladder (disorder)	K82.8 Other specified diseases of gallbladder
Bacterial infection, unspecified	A49.9 Bacterial infection, unspecified
Benign neoplasm of duodenum (disorder)	D13.2 Benign neoplasm of duodenum
Benign neoplasm of esophagus (disorder)	D13.0 Benign neoplasm of esophagus
Benign neoplasm of liver (disorder)	D13.4 Benign neoplasm of liver
Benign neoplasm of pancreas (disorder)	D13.6 Benign neoplasm of pancreas
Benign neoplasm of parotid gland (disorder)	D11.0 Benign neoplasm of parotid gland
Benign neoplasm of the peritoneum (disorder)	D20.1 Benign neoplasm of the peritoneum
Benign neoplasm of pituitary gland (disorder)	D35.2 Benign neoplasm of pituitary gland
Benign neoplasm of thymus	D15.0 Benign neoplasm of thymus
Biliary dyskinesia (disorder)	K82.8 Other specified diseases of gallbladder
Bleeding internal hemorrhoids (disorder)	K64.8 Other hemorrhoids
Calculus of gallbladder and bile duct with acute and chronic cholecystitis (disorder)	K80.66 Calculus of gallbladder and bile duct with acute and chronic cholecystitis without obstruction K80.67 Calculus of gallbladder and bile duct with acute and chronic cholecystitis with obstruction
Calculus of gallbladder and bile duct with acute cholecystitis (disorder)	K80.62 Calculus of gallbladder and bile duct with acute cholecystitis without obstruction K80.63 Calculus of gallbladder and bile duct with acute cholecystitis with obstruction
Carcinoma in situ of cervix	D06.9 Carcinoma in situ of cervix, unspecified
Cervical high risk human papillomavirus (HPV) DNA test positive	R87.810 Cervical high risk human papillomavirus (HPV) DNA test positive
Chimeric antigen receptor T-cell immunotherapy	Z92.850 Personal history of Chimeric Antigen Receptor T- cell therapy
Chronic anal fissure (disorder)	K60.1 Chronic anal fissure
Chronic parametritis and pelvic cellulitis (disorder)	N73.1 Chronic parametritis and pelvic cellulitis
Complete obstruction of intestine (disorder)	K56.601 Complete intestinal obstruction, unspecified as to cause K56.691 Other complete intestinal obstruction K56.699 Other intestinal obstruction unspecified as to partial versus complete obstruction
Crohn’s disease of small intestine with abscess	K50.014 Crohn’s disease of small intestine with abscess
Cyst of Bartholin’s gland duct (disorder)	N75.0 Cyst of Bartholin’s gland duct
Cyst of cystic duct (disorder)	K82.8 Other specified diseases of gallbladder
Cyst of gallbladder (disorder)	K82.8 Other specified diseases of gallbladder
Cyst of pancreas (disorder)	K86.2 Cyst of pancreas
Disorder of adrenal gland (disorder)	E27.9 Disorder of adrenal gland, unspecified
Drug-induced androgenic alopecia (disorder)	L64.0 – Drug-induced androgenic alopecia
Encounter for antineoplastic radiation therapy	Z51.0 Encounter for antineoplastic radiation therapy
Encounter for sterilization	Z30.2 Encounter for sterilization
Encounter for surgical aftercare following surgery on the digestive system	Z48.815 Encounter for surgical aftercare following surgery on the digestive system
Endometriosis (disorder)	N80.9 Endometriosis, unspecified
Endometriosis in cutaneous scar	N80.6 Endometriosis in cutaneous scar
Endometriosis of bladder (disorder)	N80.8 Other endometriosis
Endometriosis of fallopian tube (disorder)	N80.2 Endometriosis of fallopian tube
Endometriosis of intestine (disorder)	N80.5 Endometriosis of intestine
Endometriosis of lung (disorder)	N80.8 Other endometriosis
Endometriosis of myometrium (disorder)	N80.0 Endometriosis of uterus
Endometriosis of ovary (disorder)	N80.1 Endometriosis of ovary
Endometriosis of pelvic peritoneum (disorder)	N80.3 Endometriosis of pelvic peritoneum
Endometriosis of rectovaginal septum (disorder)	N80.4 Endometriosis of rectovaginal septum and vagina
Endometriosis of left ovary (disorder)	N80.1 Endometriosis of ovary
Endometriosis of right ovary (disorder)	N80.1 Endometriosis of ovary
Endometriosis of thorax (disorder)	N80.8 Other endometriosis
Endometriosis of umbilicus (disorder)	N80.8 Other endometriosis
Endometriosis of uterus (disorder)	N80.0 Endometriosis of uterus
Fat necrosis of bilateral breasts (disorder)	N64.1 Fat necrosis of breast
Fat necrosis of breast (disorder)	N64.1 Fat necrosis of breast
Fever, unspecified	R50.9 Fever, unspecified
Gallbladder mass (disorder)	K82.8 Other specified diseases of gallbladder
Gastrointestinal stromal tumor of stomach	C49.A2 Gastrointestinal stromal tumor of stomach
Granulomatous mastitis (disorder)	N61.20 Granulomatous mastitis, unspecified breast N61.21 Granulomatous mastitis, right breast N61.22 Granulomatous mastitis, left breast N61.23 Granulomatous mastitis, bilateral breast
Heart failure (disorder)	I50.9 Heart failure, unspecified
Hemorrhoids (disorder)	K64.9 Unspecified hemorrhoids
Hemothorax due to trauma (disorder)	S27.1XXA Traumatic hemothorax, initial encounter
Hematoma of obstetric wound (disorder)	090.2 Hematoma of obstetric wound
Hemorrhoids with complication	K64.8 Other hemorrhoids
Hirschsprung’s disease (disorder)	Q43.1 Hirschsprung’s disease
Incontinence of feces (finding)	R15.9 Full incontinence of feces
Internal hemorrhoids (disorder)	K64.8 Other hemorrhoids
Intramural calcification of gallbladder (disorder)	K82.8 Other specified diseases of gallbladder
Irritable bowel syndrome characterized by constipation (disorder)	K58.1 Irritable bowel syndrome with constipation
Hemothorax (disorder)	J94.2 Hemothorax
Homocystinuria (disorder)	E72.11 Homocystinuria (disorder)
Hypercalcemia (disorder)	E83.52 Hypercalcemia
Hyperglycemia due to diabetes mellitus (disorder)	E11.65 Type 2 diabetes mellitus with hyperglycemia
Hypertrophic disorder of the skin, unspecified	L91.9 Hypertrophic disorder of the skin, unspecified
Hypertrophy of breast (disorder)	N62 – Hypertrophy of breast
Hypertrophy of cystic duct (disorder)	K82.8 Other specified diseases of gallbladder
Hypertrophy of gallbladder (disorder)	K82.8 Other specified diseases of gallbladder
Hypovolemia (finding)	E86.1 Hypovolemia
Immunodeficiency disorder (disorder)	D84.9 Immunodeficiency, unspecified
Increased androgen level (finding)	E28.1 Androgen excess
Injury of bile duct (disorder)	S36.13XA Injury of bile duct, initial encounter S36.13XD Injury of bile duct, subsequent encounter S36.13XS Injury of bile duct, sequela
Internal hemorrhoids grade IV (disorder)	K64.3 Fourth degree hemorrhoids
Intestinal obstruction due to Crohn’s disease of large intestine	K50.112 Crohn’s disease of large intestine with intestinal obstruction
Irregular periods (finding)	N92.6 Irregular menstruation, unspecified
Knee pain	M25.561 Pain in right knee M25.562 Pain in left knee M25.569 Pain in unspecified knee
Lower abdominal pain (finding)	R10.30 Lower abdominal pain, unspecified
Lymphoproliferative disorder (disorder)	D47.9 Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
Major depression, single episode (disorder)	F32.0 Major depressive disorder, single episode, mild F32.1 Major depressive disorder, single episode, moderate F32.2 Major depressive disorder, single episode, severe without psychotic features F32.3 Major depressive disorder, single episode, severe with psychotic features F32.4 Major depressive disorder, single episode, in partial remission F32.5 Major depressive disorder, single episode, in full remission F32.9 Major depressive disorder, single episode, unspecified
Malignant melanoma of lower limb (disorder)	C43.70 Malignant melanoma of unspecified lower limb, including hip C43.71 Malignant melanoma of right lower limb, including hip C43.72 Malignant melanoma of left lower limb, including hip
Malignant melanoma of scalp and/or neck (disorder)	C43.4 Malignant melanoma of scalp and neck
Malignant neoplasm of connective and soft tissue of head face and neck	C49.0 Malignant neoplasm of connective and soft tissue of head face and neck
Malignant neoplasm of connective and soft tissue of left hip and lower limb	C49.22 Malignant neoplasm of connective and soft tissue of left lower limb, including hip
Malignant neoplasm of connective and soft tissue of right hip and lower limb	C49.21 Malignant neoplasm of connective and soft tissue of right lower limb, including hip
Malignant neoplasm of connective and soft tissue of hip and lower limb (disorder)	C49.20 Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip C49.21 Malignant neoplasm of connective and soft tissue of right lower limb, including hip C49.22 Malignant neoplasm of connective and soft tissue of left lower limb, including hip
Malignant neoplasm of connective and soft tissue of left upper limb and shoulder	C49.12 Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
Malignant neoplasm of connective and soft tissue of right upper limb and shoulder	C49.11 Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
Malignant neoplasm of connective and soft tissue of upper limb and shoulder (disorder)	C49.10 Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder
Malignant neoplasm of endocervix (disorder)	C53.0 Malignant neoplasm of endocervix
Malignant neoplasm of mandible (disorder)	C41.1 Malignant neoplasm of mandible
Malignant neoplasm of thyroid gland	C73 Primary malignant neoplasm of thyroid gland (disorder)
Malignant neoplasm of vertebral column (disorder)	C41.2 Malignant neoplasm of vertebral column
Malignant tumor of pyloric antrum (disorder)	C16.3 Malignant neoplasm of pyloric antrum
Melanocytic nevus (disorder)	D22.9 Melanocytic nevi, unspecified
Missed abortion (disorder)	O02.1 Missed abortion
Neoplasm related pain (acute)(chronic)	G89.3 Neoplasm related pain (acute)(chronic)
Neoplasm of uncertain behavior of liver, gallbladder and bile ducts	D37.6 Neoplasm of uncertain behavior of liver, gallbladder and bile ducts
Nonfunctioning cystic duct (disorder)	K82.8 Other specified diseases of gallbladder
Nonfunctioning gallbladder (disorder)	K82.8 Other specified diseases of gallbladder
Non-toxic multinodular goiter (disorder)	E04.2 Nontoxic multinodular goiter
Obstruction of bile duct (disorder)	K83.1 Obstruction of bile duct
Obstruction of esophagus (disorder)	K22.2 Esophageal obstruction
Pain in left hip (finding)	M25.552 Pain in left hip
Pain in right hip (finding)	M25.551 Pain in right hip
Pain of left knee region (finding)	M25.562 Pain in left knee
Pain of right knee region (finding)	M25.561 Pain in right knee
Peritoneal cyst	K66.8 Other specified disorders of peritoneum
Personal history of malignant neoplasm of ovary	Z85.43 Personal history of malignant neoplasm of ovary
Pleurisy (disorder)	R09.1 Pleurisy
Pneumoperitoneum (disorder)	K66.8 Other specified disorders of peritoneum
Primary hyperparathyroidism (disorder)	E21.0 Primary hyperparathyroidism
Primary malignant neoplasm of ampulla of Vater (disorder)	C24.1 Malignant neoplasm of ampulla of Vater
Primary malignant neoplasm of broad ligament (disorder)	C57.10 Malignant neoplasm of unspecified broad ligament C57.11 Malignant neoplasm of right broad ligament C57.12 Malignant neoplasm of left broad ligament
Primary malignant neoplasm of maxillary sinus (disorder)	C31.0 Malignant neoplasm of maxillary sinus
Primary malignant neoplasm of pyloric antrum (disorder)	C16.3 Malignant neoplasm of pyloric antrum
Primary malignant neoplasm of renal pelvis (disorder)	C65.1 Malignant neoplasm of right renal pelvis C65.2 Malignant neoplasm of left renal pelvis C65.9 Malignant neoplasm of unspecified renal pelvis
Primary malignant neoplasm of soft tissues of face (disorder)	C49.0 Malignant neoplasm of connective and soft tissue of head face and neck
Primary malignant neoplasm of soft tissues of head (disorder)	C49.0 Malignant neoplasm of connective and soft tissue of head face and neck
Primary malignant neoplasm of soft tissues of neck (disorder)	C49.0 Malignant neoplasm of connective and soft tissue of head face and neck
Primary malignant neoplasm of testis (disorder)	C62.10 Malignant neoplasm of unspecified descended testis C62.11 Malignant neoplasm of descended right testis C62.12 Malignant neoplasm of descended left testis
Primary malignant neoplasm of vertebral column (disorder)	C41.2 Malignant neoplasm of vertebral column
Primary malignant neoplasm of vulva (disorder)	C51.9 Malignant neoplasm of vulva, unspecified
Prolapsed hemorrhoids (disorder)	K64.8 Other hemorrhoids
Prolapsed external hemorrhoids (disorder)	K64.8 Other hemorrhoids
Prolapsed internal hemorrhoids (disorder)	K64.8 Other hemorrhoids
Pyothorax with fistula	J86.0 Pyothorax with fistula
Pyothorax without fistula	J86.9 Pyothorax without fistula
Screening for malignant neoplasm of cervix (procedure)	Z12.4 Encounter for screening for malignant neoplasm of cervix
Secondary malignant neoplasm of liver and intrahepatic bile duct	C78.7 Secondary malignant neoplasm of liver and intrahepatic bile duct
Secondary malignant neoplasm of small intestine (disorder)	C78.4 – Secondary malignant neoplasm of small intestine
Strangulated hemorrhoids (disorder)	K64.8 Other hemorrhoids
Strangulated internal hemorrhoids (disorder)	K64.8 Other hemorrhoids
Ulcerated hemorrhoids (disorder)	K64.8 Other hemorrhoids
Ulcerated external hemorrhoids (disorder)	K64.8 Other hemorrhoids
Ulcerated internal hemorrhoids (disorder)	K64.8 Other hemorrhoids
Ulcer of cystic duct (disorder)	K82.8 Other specified diseases of gallbladder
Ulcer of gallbladder (disorder)	K82.8 Other specified diseases of gallbladder
Unspecified abdominal pain	R10.9 Unspecified abdominal pain
Unspecified intestinal obstruction	K56.609 Unspecified intestinal obstruction, unspecified as to partial versus complete obstruction
Upper urinary tract infection (disorder)	N39.0 – Urinary tract infection, site not specified
Uterine leiomyoma (disorder)	D25.9 Leiomyoma of uterus, unspecified
Vaginal high risk human papillomavirus (HPV) DNA test positive	R87.811 Vaginal high risk human papillomavirus (HPV) DNA test positive
Wegener’s granulomatosis with renal involvement (disorder)	M31.31 – Wegener’s granulomatosis with renal involvement
Wegener’s granulomatosis without renal involvement (disorder)	M31.30 – Wegener’s granulomatosis without renal involvement